400 related articles for article (PubMed ID: 21881526)
1. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
[TBL] [Abstract][Full Text] [Related]
2. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
[TBL] [Abstract][Full Text] [Related]
4. Ginkgo biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells.
Ji L; Yin XX; Wu ZM; Wang JY; Lu Q; Gao YY
Phytother Res; 2009 Apr; 23(4):477-85. PubMed ID: 19003945
[TBL] [Abstract][Full Text] [Related]
5. The effects of high glucose and atorvastatin on endothelial cell matrix production.
McGinn S; Poronnik P; Gallery ED; Pollock CA
Diabet Med; 2004 Oct; 21(10):1102-7. PubMed ID: 15384957
[TBL] [Abstract][Full Text] [Related]
6. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE
Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of rosuvastatin in the regulation of metalloproteinase expression.
Sapienza P; Borrelli V; Sterpetti AV; Dinicola S; Tartaglia E; di Marzo L
Ann Vasc Surg; 2011 Aug; 25(6):823-9. PubMed ID: 21620672
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
9. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
11. Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells.
Ho FM; Liu SH; Lin WW; Liau CS
J Cell Biochem; 2007 May; 101(2):442-50. PubMed ID: 17203468
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
13. [Effects of overexpression of decorin on matrix metalloproteinases 2 and 9 in rat mesangial and tubular cells].
Dong FQ; Li H; Wu F; Yao HP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3444-7. PubMed ID: 19159581
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
15. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis.
Milner JM; Rowan AD; Cawston TE; Young DA
Arthritis Res Ther; 2006; 8(5):R142. PubMed ID: 16919164
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis.
Siddiqui AJ; Gustafsson T; Sylven C; Crisby M
Pharmacology; 2014; 93(3-4):178-84. PubMed ID: 24854110
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
Zafiriou S; Stanners SR; Saad S; Polhill TS; Poronnik P; Pollock CA
J Am Soc Nephrol; 2005 Mar; 16(3):638-45. PubMed ID: 15689403
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
